MCRB
Seres Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Seres Therapeutics has 5 disclosed suppliers and 6 disclosed customers in SEC filings.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
SentenceAs consideration for the Transaction, SPN agreed to pay us: (i) a cash payment, which was paid at Closing, of $100 million, less approximately $17.9 million owed by us to an affiliate of SPN as of March 31, 2024 under the prior license agreement between us and the SPN affiliate, less approximately CHF 2.0 million in satisfaction of fees due under an existing manufacturing agreement between us and Bacthera; (ii) cash installment payments of $50 million, which was received on January 15, 2025 and $25 million, which was received on July 1, 2025, (offset by $1.4 million paid by us to Nestl é on July 1, 2025 related to certain employment obligations assumed by SPN, as described below), conditioned on our material compliance with obligations under the TSA entered into at Closing between us and NESA; (iii) prepayment of the $60 million Prepaid Milestone tied to the achievement of the First Sales Milestone of worldwide annual net sales of the Product of $150 million, which was paid in cash at Closing, which Prepaid Milestone will accrue interest at a fixed rate of 10% per annum until the First Sales Milestone is achieved and 5% per annum thereafter until the earlier of (x) the date on which the Prepaid Milestone, plus accrued interest thereon, has been repaid in full by set-off and (y) the last day of the Milestone Period; and (iv) future Milestone Payments of (x) $125 million tied to the achievement of worldwide annual net sales of the Product of $400 million and (y) $150 million tied to the achievement of worldwide annual net sales of the Product of $750 million, during the Milestone Period from Closing until December 31 of the calendar year in which the tenth anniversary of Closing occurs.
MCRB 10-Kaccession 0001193125-26-103276
SentenceThe CARB-X grant provides us with up to $3.6 million of funding for research, manufacture, and design of a Phase 1 clinical trial in ICU patients.
MCRB 10-Kaccession 0001193125-26-103276
SentenceDevelopment of LBP-LF is ongoing with grant support from CARB-X and in collaboration with Columbia University.
MCRB 10-Kaccession 0001193125-26-103276
SentenceIn October 2023, we were awarded a $500,000 grant from the CCF to leverage our clinical results and biological mechanism insights to functionally characterize subpopulations and to define associated biomarkers for IBD patient selection and stratification of patients where the GI microbiome plays an active role in inflammation and could be modified to reduce colitis.
MCRB 10-Kaccession 0001193125-26-103276
SentenceWe have been collaborating with Memorial Sloan Kettering Cancer Center for over a decade on the impact of the GI microbiome on immune related diseases and cancer; recently this long-standing collaboration included an investigator-sponsored trial, or IST, evaluating SER-155 in 15 participants with irEC.
MCRB 10-Kaccession 0001193125-26-103276
SentenceUnder the TSA with NESA, beginning in the fourth quarter of 2024, we provided certain manufacturing services and related functions of the VOWST Business and operations.
MCRB 10-Kaccession 0001193125-26-103276
Sentence
The change in other income (expense), net was primarily due to the $75.0 million of installment payments received from Nestlé in January and July 2025, which were conditioned on our material compliance with obligations under the TSA, an increase of $7.0 million of reimbursement income from Nestlé associated with the performance of TSA services, and $0.6 million increase in sublease income.
MCRB 10-Kaccession 0001193125-26-103276
SentenceOf the issued U.S. patents, 13 U.S. patents (including one as licensee) have been assigned to Nestlé Health Science as part of its purchase of VOWST.
MCRB 10-Kaccession 0001193125-26-103276
SentenceWe led the successful development and approval of VOWST, the first FDA-approved orally administered microbiome biotherapeutic and a Breakthrough Therapy designated drug, which was sold to Société des Produits Nestlé S.A., or SPN, and with certain of its affiliates, collectively, Nestlé Health Science, in September 2024.
MCRB 10-Kaccession 0001193125-26-103276
SentenceWe led the successful development and approval of VOWST, the first FDA-approved orally administered microbiome biotherapeutic and a Breakthrough Therapy designated drug, which was sold to Société des Produits Nestlé S.A., or SPN, and with certain of its affiliates, collectively, Nestlé Health Science, in September 2024.
MCRB 10-Kaccession 0001193125-26-103276
SentenceWe have only developed one FDA-approved product, VOWST, which was sold to SPN in September 2024.
MCRB 10-Kaccession 0001193125-26-103276
Seres Therapeutics, Inc.
1.76
Largest filed tie
—
Expected move
Inputsspot 1.77exp Nov 20ATM strike 2.5ATM straddle 0.75IV 79%